An observational study in Persistent Pulmonary Hypertension of the Newborn, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged Up to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Medical College of Wisconsin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is one of 3 that started in 2006, is one of 4 observational ones, and was the 7th registered.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
Browse Persistent Fetal Circulation Syndrome studies →1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: Up to 12 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 125 across 12 observational studies indexed under Persistent Fetal Circulation Syndrome.
Median enrollment 38 across the 12 interventional studies, 106 across the 4 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 1 study filed under Persistent Fetal Circulation Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
Persistent pulmonary hypertension of the newborn (PPHN) occurs when the pulmonary vascular resistance fails to decrease at birth during the transition to postnatal life. The affected infants have severe hypoxemia, a 10% risk of mortality, and among survivors, a 30% incidence of long term neurodevelopmental and hearing deficits. The etiology of PPHN in the majority of affected infants remains unknown. Although constriction of fetal ductus arteriosus in response to maternal intake of non-steroidal anti-inflammatory drugs (NSAID) has been implicated in PPHN case reports, our laboratory was the first to provide objective evidence for such an association. Nearly 87% of infants with PPHN were exposed to NSAID in utero. Yet 25% of control infants also were exposed without developing PPHN. The basis for the biological susceptibility of some neonates to in utero NSAID exposure remains poorly understood. The hypothesis of this proposal is that PTGS1 genetic variation is associated with increased susceptibility to ductal constriction from in utero NSAID exposure and an increased risk of PPHN. This hypothesis will be tested through the following specific aims: Determine the incidence of PTGS1 sequence variants in PPHN patients versus matched controls. PTGS1 sequence will include all 11 exons, a minimum of 100 bp of exon flanking sequences, and 1 kbp of upstream regulatory information. Cycle sequencing will be performed followed by analysis using capillary electrophoresis. Differences in the frequency of sequence variants will be determined using Fisher's exact test. The study will also quantify NSAID exposure in meconium samples using a previously established GC/MS assay and correlate exposure levels to both the incidence of PPHN and the presence or absence of PTGS1 sequence variants using regression analysis. Benefits include the ability to predict risk for PPHN based on PTGS1 sequence and avoidance of such risk in the future, thereby reducing patient morbidity and mortality.
Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants born at \>= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
Randomly selected, normal healthy infants born at \>= 34 weeks gestational age and do not have PPHN
To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.
Time frame: participants will be followed for the duration of hospital stay, an expected average of 3 weeks
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2006, a primary completion of Dec 2027 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Persistent Fetal Circulation Syndrome →
Medical College of Wisconsin →